ANEB (Anebulo Pharmaceuticals) Ending Cash Position: $9.04 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ANEB Anebulo Pharmaceuticals Inc ANEB
35 GF Score
Price $0.33
! 1 Warning Sign
View Full Analysis

What is Anebulo Pharmaceuticals Ending Cash Position?

Anebulo Pharmaceuticals ANEB 35 Ending Cash Position is $9.04 Mil as of Dec. 2025. GuruFocus rates ANEB with a GF Score™ of 35/100. The stock has 1 warning sign investors should review.

Anebulo Pharmaceuticals's Ending Cash Position for the quarter that ended in Dec. 2025 was $9.04 Mil.

Anebulo Pharmaceuticals's quarterly Ending Cash Position declined from Jun. 2025 ($11.63 Mil) to Sep. 2025 ($10.36 Mil) and declined from Sep. 2025 ($10.36 Mil) to Dec. 2025 ($9.04 Mil).

Anebulo Pharmaceuticals's annual Ending Cash Position declined from Jun. 2023 ($11.25 Mil) to Jun. 2024 ($3.09 Mil) but then increased from Jun. 2024 ($3.09 Mil) to Jun. 2025 ($11.63 Mil).

Anebulo Pharmaceuticals Ending Cash Position Related Terms

Anebulo Pharmaceuticals Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Anebulo Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anebulo Pharmaceuticals Ending Cash Position Chart

Anebulo Pharmaceuticals Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Ending Cash Position
Get a 7-Day Free Trial 19.99 14.55 11.25 3.09 11.63

Anebulo Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.00 13.28 11.63 10.36 9.04
ANEB
35GF Score
Anebulo Pharmaceuticals Inc ANEB
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anebulo Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Anebulo Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Jun. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=3.095+8.533
=11.63

Anebulo Pharmaceuticals's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=10.355+-1.313
=9.04

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $9.04 Mil mean?
Anebulo Pharmaceuticals (ANEB) has a Ending Cash Position of $9.04 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Anebulo Pharmaceuticals and its competitors.
Is Anebulo Pharmaceuticals' Ending Cash Position too high?
Anebulo Pharmaceuticals' current Ending Cash Position is $9.04 Mil. Overall, Anebulo Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Anebulo Pharmaceuticals' Ending Cash Position compare to PHIO and COCP?
Anebulo Pharmaceuticals' Ending Cash Position of $9.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Anebulo Pharmaceuticals and its competitors. Anebulo Pharmaceuticals's current Ending Cash Position is $9.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anebulo Pharmaceuticals stock overvalued right now?
Anebulo Pharmaceuticals (ANEB) has a current Ending Cash Position of $9.04 Mil. The current Ending Cash Position is $9.04 Mil. Anebulo Pharmaceuticals' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Anebulo Pharmaceuticals (ANEB), the current Ending Cash Position is $9.04 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anebulo Pharmaceuticals Business Description

Address 1017 Ranch Road 620 South, Suite 107, Lakeway, TX, USA, 78734
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.
35GF Score

Get the complete analysis for ANEB

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.33
Price